{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-095424","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2026-08-13T11:00:19+00:00","discovered_at":"2026-08-13T11:05:00.607698+00:00","generated_at":"2026-08-13T11:05:44.759891+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"PTC wins bankruptcy auction for Sangamo's Fabry gene therapy ST-920; $111M upfront","bullets":["Deal: $111M upfront plus up to $100M milestones ($80M on accelerated approval, $20M on traditional FDA approval).","ST-920 is a one-time AAV gene therapy; BLA submission for accelerated approval expected Q4 2026.","Phase 1/2 STAAR data showed positive eGFR slope at 52 weeks; durability up to 4.5 years in earliest patient.","Close expected late Q3/early Q4 2026, subject to bankruptcy court approval, antitrust review, and customary conditions.","PTC expects no impact on 2026 cash flow break-even; leverages existing rare disease commercial infrastructure."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-095424","json":"https://secwatch.observer/filing/0001104659-26-095424.json","markdown":"https://secwatch.observer/filing/0001104659-26-095424.md","text":"https://secwatch.observer/filing/0001104659-26-095424.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000110465926095424/0001104659-26-095424-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000110465926095424/tmb-20260812x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T11:05:44.759891+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}